There are 3161 resources available
Medical oncologist perspective
Presenter: Laura Biganzoli
Session: ESMO-SIOG: Working together in the era of personalized care for older adults with cancer
Resources:
Slides
Webcast
Discussion
Session: Survivors of advanced melanoma: Management and support
Resources:
Webcast
Q&A
Session: Proffered Paper session 2: GU, non-prostate
Resources:
Webcast
71MO - Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial
Presenter: Adi Diab
Session: Mini oral session: Basic science & Translational research
Resources:
Abstract
Webcast
1504MO - Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
Presenter: Wungki Park
Session: Mini oral session: GI tumours, upper
Resources:
Abstract
Slides
Webcast
LBA23 - ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria
Presenter: Juan De la Haba Rodriguez
Session: Mini oral session 2: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
CN69 - The effect of an empowerment program on ruminative thoughts, fatigue and psychological resilience of cancer survivors: A randomized controlled trial
Presenter: Sinem Öcalan
Session: Rehabilitation and survivorship care
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: ESMO-SIOG: Working together in the era of personalized care for older adults with cancer
Resources:
Webcast
Invited Discussant LBA63 and 1504MO
Presenter: Arndt Vogel
Session: Mini oral session: GI tumours, upper
Resources:
Slides
Webcast
72MO - Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effectively than when given sequentially or with anti-PD-1 alone
Presenter: Jorja Braden
Session: Mini oral session: Basic science & Translational research
Resources:
Abstract
Slides
Webcast